Today, the A-share market rose and fell, chips, software and other sectors rose first, the pharmaceutical sector was weak and volatile, and the CSI Pharmaceutical Index (000933) fell slightly by 0.4%. In terms of constituent stocks, Yirui Technology (688301) led the rise of 7.6%, United Imaging Medical (688271) and BGI (300676) rose by more than 5%, and Mindray Medical and Rongchang Biotech were among the top gainers; Haisco (002653) led the decline by more than 5%, the common people (603883) fell by 4.72%, Aimeike (300896) fell by 3.27%, and Aier Ophthalmology and Kailaiying were among the top decliners.

In terms of popular ETFs, the pharmaceutical ETF (159929), which tracks the CSI Pharmaceutical Index, opened high and fell 0.5%, with the latest price of 1.386 yuan, an intraday turnover of nearly 300 million yuan, and a turnover rate of over 10%, with active trading.

In the long run, as of November 7, 2024, the pharmaceutical ETF has risen by 6.58% in the past 1 week.

In terms of scale, the latest scale of pharmaceutical ETF (159929) reached 2.529 billion yuan, a record high.

In terms of net inflow of funds, pharmaceutical ETF (159929) has had a net inflow of funds for 7 days in the past 10 trading days, with a total of 84.8525 million yuan of "gold absorption", and an average daily net inflow of 8.4852 million yuan. Today's intraday net subscription exceeded 37 million yuan

The data shows that leveraged funds continue to be deployed. The latest financing purchase amount of pharmaceutical ETF reached 22.9774 million yuan, and the latest financing balance reached 159 million yuan.

BOCOM International pointed out that the number of varieties of the tenth batch of drugs purchased by the country is the largest in history and the highest entry threshold in history, and it is expected that the follow-up will increase the elimination efforts, which will bring certain competitive pressure to pharmaceutical companies. At the same time, the proportion of injections in this round of national procurement has also reached a record high, as a drug that strongly depends on the development of hospitals, the competition pattern of related pharmaceutical companies may change in the future. Recently, the pharmaceutical sector has rebounded slightly after a sharp shock, considering that the valuation of the sector is still at a historical bottom, and there is still room for further repair due to the introduction of subsequent macro favorable policies + improved liquidity.

Investors who are optimistic about the overall pharmaceutical sector can get on the bus with one click through the pharmaceutical ETF (159929).

According to the data, the CSI Pharmaceutical Index (000933) tracked by the Pharmaceutical ETF (159929) fully covers the subdivision of the pharmaceutical sector. According to the data, as of October 25, 2024, the top ten weighted stocks of the CSI Healthcare Index (000933) are Hengrui Pharmaceutical, Mindray Pharmaceutical, WuXi AppTec, Pien Tze Huang, Aier Ophthalmology, Yunnan Baiyao, Xinhecheng, United Imaging Medical, Shanghai RAAS, and Zhifei Biotech, with the top ten weighted stocks accounting for 43.89% in total.

Risk Warning: Funds are risky, and investment should be cautious. This material is promotional material only and is not intended as any legal document. Investors should carefully read the Fund Contract, Prospectus and Key Facts Statement and other legal documents to understand the product information in detail. Pharmaceutical ETF is a higher risk level (R4) product, which is suitable for investors who are aggressive (C4) and above after the customer's risk level assessment. The information in this article is for reference only, and investors must be responsible for any investment behavior determined independently. The individual stocks mentioned in the article are only objectively displayed and enumerated by the constituent stocks of the index, and the information appearing in this article is for reference only, and investors must be responsible for any investment behavior determined independently. Any opinions, analyses and forecasts contained in this article do not constitute investment advice of any kind to the reader.